Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Activation of liver X receptor up-regulates the expression of the NKG2D ligands MICA and MICB in multiple myeloma through different molecular mechanisms.

Bilotta MT, Abruzzese MP, Molfetta R, Scarno G, Fionda C, Zingoni A, Soriani A, Garofalo T, Petrucci MT, Ricciardi MR, Paolini R, Santoni A, Cippitelli M.

FASEB J. 2019 May 24:fj201900319R. doi: 10.1096/fj.201900319R. [Epub ahead of print]

PMID:
31125275
2.

The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.

Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M.

Cell Death Dis. 2019 Apr 11;10(4):324. doi: 10.1038/s41419-019-1562-9.

3.

The Ubiquitin-proteasome pathway regulates Nectin2/CD112 expression and impairs NK cell recognition and killing.

Molfetta R, Milito ND, Zitti B, Lecce M, Fionda C, Cippitelli M, Santoni A, Paolini R.

Eur J Immunol. 2019 Jun;49(6):873-883. doi: 10.1002/eji.201847848. Epub 2019 Mar 27.

PMID:
30888046
4.

Translating the anti-myeloma activity of Natural Killer cells into clinical application.

Fionda C, Stabile H, Molfetta R, Soriani A, Bernardini G, Zingoni A, Gismondi A, Paolini R, Cippitelli M, Santoni A.

Cancer Treat Rev. 2018 Nov;70:255-264. doi: 10.1016/j.ctrv.2018.10.005. Epub 2018 Oct 10. Review.

PMID:
30326421
5.

Abnormal regulation of BCR signalling by c-Cbl in chronic lymphocytic leukaemia.

Martini V, Frezzato F, Severin F, Raggi F, Trimarco V, Martinello L, Molfetta R, Visentin A, Facco M, Semenzato G, Paolini R, Trentin L.

Oncotarget. 2018 Aug 14;9(63):32219-32231. doi: 10.18632/oncotarget.25951. eCollection 2018 Aug 14.

6.

NKG2D and Its Ligands: "One for All, All for One".

Zingoni A, Molfetta R, Fionda C, Soriani A, Paolini R, Cippitelli M, Cerboni C, Santoni A.

Front Immunol. 2018 Mar 12;9:476. doi: 10.3389/fimmu.2018.00476. eCollection 2018. Review.

7.

Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells.

Zitti B, Molfetta R, Fionda C, Quatrini L, Stabile H, Lecce M, de Turris V, Ricciardi MR, Petrucci MT, Cippitelli M, Gismondi A, Santoni A, Paolini R.

Sci Rep. 2017 Sep 5;7(1):10445. doi: 10.1038/s41598-017-10403-0.

8.

Regulation of NKG2D-Dependent NK Cell Functions: The Yin and the Yang of Receptor Endocytosis.

Molfetta R, Quatrini L, Santoni A, Paolini R.

Int J Mol Sci. 2017 Aug 2;18(8). pii: E1677. doi: 10.3390/ijms18081677. Review.

9.

3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells.

Parlato S, De Ninno A, Molfetta R, Toschi E, Salerno D, Mencattini A, Romagnoli G, Fragale A, Roccazzello L, Buoncervello M, Canini I, Bentivegna E, Falchi M, Bertani FR, Gerardino A, Martinelli E, Natale C, Paolini R, Businaro L, Gabriele L.

Sci Rep. 2017 Apr 24;7(1):1093. doi: 10.1038/s41598-017-01013-x.

10.

Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production.

Capuano C, Pighi C, Molfetta R, Paolini R, Battella S, Palmieri G, Giannini G, Belardinilli F, Santoni A, Galandrini R.

Oncoimmunology. 2017 Feb 10;6(3):e1290037. doi: 10.1080/2162402X.2017.1290037. eCollection 2017.

11.

Genotoxic stress modulates the release of exosomes from multiple myeloma cells capable of activating NK cell cytokine production: Role of HSP70/TLR2/NF-kB axis.

Vulpis E, Cecere F, Molfetta R, Soriani A, Fionda C, Peruzzi G, Caracciolo G, Palchetti S, Masuelli L, Simonelli L, D'Oro U, Abruzzese MP, Petrucci MT, Ricciardi MR, Paolini R, Cippitelli M, Santoni A, Zingoni A.

Oncoimmunology. 2017 Jan 13;6(3):e1279372. doi: 10.1080/2162402X.2017.1279372. eCollection 2017.

12.

p38 MAPK differentially controls NK activating ligands at transcriptional and post-transcriptional level on multiple myeloma cells.

Soriani A, Borrelli C, Ricci B, Molfetta R, Zingoni A, Fionda C, Carnevale S, Abruzzese MP, Petrucci MT, Ricciardi MR, La Regina G, Di Cesare E, Lavia P, Silvestri R, Paolini R, Cippitelli M, Santoni A.

Oncoimmunology. 2016 Dec 2;6(1):e1264564. doi: 10.1080/2162402X.2016.1264564. eCollection 2017.

13.

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.

Abruzzese MP, Bilotta MT, Fionda C, Zingoni A, Soriani A, Vulpis E, Borrelli C, Zitti B, Petrucci MT, Ricciardi MR, Molfetta R, Paolini R, Santoni A, Cippitelli M.

J Hematol Oncol. 2016 Dec 1;9(1):134.

14.

Regulation of NKG2D Expression and Signaling by Endocytosis.

Molfetta R, Quatrini L, Zitti B, Capuano C, Galandrini R, Santoni A, Paolini R.

Trends Immunol. 2016 Nov;37(11):790-802. doi: 10.1016/j.it.2016.08.015. Epub 2016 Sep 22. Review.

PMID:
27667711
15.

Ubiquitin-dependent endocytosis of NKG2D-DAP10 receptor complexes activates signaling and functions in human NK cells.

Quatrini L, Molfetta R, Zitti B, Peruzzi G, Fionda C, Capuano C, Galandrini R, Cippitelli M, Santoni A, Paolini R.

Sci Signal. 2015 Oct 27;8(400):ra108. doi: 10.1126/scisignal.aab2724.

PMID:
26508790
16.

Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma - a case report.

Gruszka AM, Rabascio C, Cannella L, Sammassimo S, Andreola G, Gregato G, Faretta M, Calleri A, De Molfetta R, Pruneri G, Bertolini F, Alcalay M.

Sci Rep. 2015 Oct 6;5:14829. doi: 10.1038/srep14829.

17.

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.

Fionda C, Abruzzese MP, Zingoni A, Cecere F, Vulpis E, Peruzzi G, Soriani A, Molfetta R, Paolini R, Ricciardi MR, Petrucci MT, Santoni A, Cippitelli M.

Oncotarget. 2015 Sep 15;6(27):23609-30.

18.

Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells.

Capuano C, Romanelli M, Pighi C, Cimino G, Rago A, Molfetta R, Paolini R, Santoni A, Galandrini R.

Cancer Res. 2015 Oct 1;75(19):4097-108. doi: 10.1158/0008-5472.CAN-15-0781. Epub 2015 Jul 30.

19.

Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells.

Zingoni A, Cecere F, Vulpis E, Fionda C, Molfetta R, Soriani A, Petrucci MT, Ricciardi MR, Fuerst D, Amendola MG, Mytilineos J, Cerboni C, Paolini R, Cippitelli M, Santoni A.

J Immunol. 2015 Jul 15;195(2):736-48. doi: 10.4049/jimmunol.1402643. Epub 2015 Jun 12.

20.

Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.

Fionda C, Abruzzese MP, Zingoni A, Soriani A, Ricci B, Molfetta R, Paolini R, Santoni A, Cippitelli M.

BMC Cancer. 2015 Jan 22;15:17. doi: 10.1186/s12885-015-1023-5.

21.

NK cells and interferons.

Paolini R, Bernardini G, Molfetta R, Santoni A.

Cytokine Growth Factor Rev. 2015 Apr;26(2):113-20. doi: 10.1016/j.cytogfr.2014.11.003. Epub 2014 Nov 13. Review.

PMID:
25443799
22.

Regulation of fc receptor endocytic trafficking by ubiquitination.

Molfetta R, Quatrini L, Gasparrini F, Zitti B, Santoni A, Paolini R.

Front Immunol. 2014 Sep 18;5:449. doi: 10.3389/fimmu.2014.00449. eCollection 2014. Review.

23.

c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.

Molfetta R, Quatrini L, Capuano C, Gasparrini F, Zitti B, Zingoni A, Galandrini R, Santoni A, Paolini R.

Eur J Immunol. 2014 Sep;44(9):2761-70. doi: 10.1002/eji.201444512. Epub 2014 Jun 17.

24.

Syk-dependent regulation of Hrs phosphorylation and ubiquitination upon FcεRI engagement: impact on Hrs membrane/cytosol localization.

Gasparrini F, Molfetta R, Quatrini L, Frati L, Santoni A, Paolini R.

Eur J Immunol. 2012 Oct;42(10):2744-53. doi: 10.1002/eji.201142278. Epub 2012 Jul 25.

25.

PIP2-dependent regulation of Munc13-4 endocytic recycling: impact on the cytolytic secretory pathway.

Capuano C, Paolini R, Molfetta R, Frati L, Santoni A, Galandrini R.

Blood. 2012 Mar 8;119(10):2252-62. doi: 10.1182/blood-2010-12-324160. Epub 2012 Jan 23.

26.

Cbl family proteins: balancing FcεRI-mediated mast cell and basophil activation.

Gasparrini F, Molfetta R, Santoni A, Paolini R.

Int Arch Allergy Immunol. 2011;156(1):16-26. doi: 10.1159/000322236. Epub 2011 Mar 29. Review.

PMID:
21447956
27.

Ubiquitination and endocytosis of the high affinity receptor for IgE.

Molfetta R, Gasparrini F, Santoni A, Paolini R.

Mol Immunol. 2010 Sep;47(15):2427-34. doi: 10.1016/j.molimm.2010.06.003. Epub 2010 Jul 16. Review.

PMID:
20638130
28.

Lipid raft-dependent FcepsilonRI ubiquitination regulates receptor endocytosis through the action of ubiquitin binding adaptors.

Molfetta R, Gasparrini F, Peruzzi G, Vian L, Piccoli M, Frati L, Santoni A, Paolini R.

PLoS One. 2009;4(5):e5604. doi: 10.1371/journal.pone.0005604. Epub 2009 May 19.

29.

Anaemia as an inflammation-mediated condition during chronic heart failure. Possible role of fibrinogen.

Morelli S, Di Girolamo F, Angelino A, Fravolini F, Mancusi C, Diurni V, Molfetta R, Acconcia C, Balsano F.

Acta Cardiol. 2008 Oct;63(5):565-70.

PMID:
19013998
30.

The adaptor molecule CIN85 regulates Syk tyrosine kinase level by activating the ubiquitin-proteasome degradation pathway.

Peruzzi G, Molfetta R, Gasparrini F, Vian L, Morrone S, Piccoli M, Frati L, Santoni A, Paolini R.

J Immunol. 2007 Aug 15;179(4):2089-96.

31.

Negative signals from FcepsilonRI engagement attenuate mast cell functions.

Molfetta R, Peruzzi G, Santoni A, Paolini R.

Arch Immunol Ther Exp (Warsz). 2007 Jul-Aug;55(4):219-29. Epub 2007 Jul 23. Review.

PMID:
17659377
32.

CIN85 regulates the ligand-dependent endocytosis of the IgE receptor: a new molecular mechanism to dampen mast cell function.

Molfetta R, Belleudi F, Peruzzi G, Morrone S, Leone L, Dikic I, Piccoli M, Frati L, Torrisi MR, Santoni A, Paolini R.

J Immunol. 2005 Oct 1;175(7):4208-16.

33.

An unusual association of malignant melanoma and small cell lung cancer: case report. An eleven-year-follow-up.

Bruno G, Coppola M, Eleuteri E, Barucco M, Molfetta R, Bruno A, Angelini L.

Clin Ter. 2003 Jul-Aug;154(4):271-5. Review.

PMID:
14618946
34.

The role of substance P in cerebral ischemia.

Bruno G, Tega F, Bruno A, Graf U, Corelli F, Molfetta R, Barucco M.

Int J Immunopathol Pharmacol. 2003 Jan-Apr;16(1):67-72.

PMID:
12578734
35.

Activation of Syk tyrosine kinase is required for c-Cbl-mediated ubiquitination of Fcepsilon RI and Syk in RBL cells.

Paolini R, Molfetta R, Beitz LO, Zhang J, Scharenberg AM, Piccoli M, Frati L, Siraganian R, Santoni A.

J Biol Chem. 2002 Oct 4;277(40):36940-7. Epub 2002 Jul 26.

36.

NGF-dependent and tissue-specific transcription of vgf is regulated by a CREB-p300 and bHLH factor interaction.

Mandolesi G, Gargano S, Pennuto M, Illi B, Molfetta R, Soucek L, Mosca L, Levi A, Jucker R, Nasi S.

FEBS Lett. 2002 Jan 2;510(1-2):50-6.

37.

Ubiquitination and degradation of Syk and ZAP-70 protein tyrosine kinases in human NK cells upon CD16 engagement.

Paolini R, Molfetta R, Piccoli M, Frati L, Santoni A.

Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9611-6. Epub 2001 Aug 7.

38.

Tyrosine kinase-dependent ubiquitination of CD16 zeta subunit in human NK cells following receptor engagement.

Paolini R, Serra A, Molfetta R, Piccoli M, Frati L, Santoni A.

Eur J Immunol. 1999 Oct;29(10):3179-87.

Supplemental Content

Loading ...
Support Center